ORIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oric Pharmaceuticals Inc (ORIC) is not a strong buy at the moment for a beginner investor with a long-term focus. While analysts maintain a positive outlook with high price targets, the current technical indicators, options sentiment, and financial performance suggest caution. The stock has experienced significant insider and hedge fund selling, and its financials show declining net income and EPS. Given the lack of immediate positive catalysts and the bearish technical trend, it's better to wait for clearer signs of recovery or stability before investing.
The MACD is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral at 49.952, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading below key resistance levels (R1: 10.723, R2: 11.596) and above support levels (S1: 7.896, S2: 7.023). Overall, the technical trend is bearish.
with Buy ratings. The company's rinzimetostat shows a favorable safety profile compared to competitors, which could drive long-term growth.
and a bearish short-term trend, with a 70% chance of declining further in the next day, week, and month.
In Q4 2025, revenue remained at $0 with no growth. Net income dropped by 15.98% YoY to -$30.51M, and EPS fell by 41.18% YoY to -0.3. Gross margin remained at 0%. The financial performance shows no signs of improvement.
Analysts maintain Buy ratings with price targets ranging from $17 to $25. They believe the market overreacted to recent data and view the stock's pullback as an attractive entry point. However, one analyst lowered the price target from $20 to $17, citing a lack of differentiation in efficacy but acknowledging a tolerability advantage.
